Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

by Anand Patadiya | Oct 2, 2024

September 23, 2024 (Cambridge, MA) – Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings...

Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

by Anand Patadiya | Sep 20, 2024

ANK-101 is a novel first-in-class anchored IL-12 immunotherapy designed for limited intratumoral delivery to increase immune cell infiltration into tumors, with potential to improve outcomes of patients treated with immune checkpoint inhibitors CAMBRIDGE, Mass. –...

Ankyra Therapeutics Presents Preliminary Phase 1 Canine Clinical Data Evaluating cANK-101 to Treat Advanced Malignant Melanoma in Dogs

by Anand Patadiya | Sep 20, 2024

First-in-class anchored IL-12 immunotherapy increases immune cell infiltration into tumors while decreasing systemic toxicity Human ANK-101, an IL-12- based anchored immunotherapy, will begin Phase 1 clinical studies in 2024 CAMBRIDGE, MA – October 14, 2023...

Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors

by Anand Patadiya | Sep 20, 2024

Clearance from U.S. Food & Drug Administration and Health Canada permits Phase I open-label dose escalation study to begin in first quarter of 2024 IL-12- based anchored immunotherapy increases immune cell infiltration into tumors while decreasing systemic...

Ankyra Therapeutics Announces Promising Preclinical Data on ANK-101, a Novel Anchored Immune Medicine, in Combination with Cytotoxic Chemotherapy in Head and Neck Cancer Model

by Anand Patadiya | Sep 20, 2024

First-in-class anchored IL-12 immunotherapy mANK-101 shows tumor growth delay in murine models as a monotherapy and in combination with platinum and anti-PD-1 Data presented at the Society for Immunotherapy of Cancer in San Diego pave the way for ANK-101 as...